REG - Tissue Regenix Group - Company update

Tissue RegenixAnnouncement

18/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250318:nRSR9901Aa&default-theme=true

RNS Number : 9901A  Tissue Regenix Group PLC  18 March 2025

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

Company update

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that further to the announcement made on 30 January 2025
(https://www.londonstockexchange.com/news-article/TRX/full-year-trading-update/16876033)
, the Company continues to execute on its 4S strategy and trading remains in
line with the Board's expectations, as the Group looks to drive further growth
in 2025.

 

The Company's review of strategic options is ongoing and as a consequence of
this, it is expected that the Final Results for the year ended 31 December
2024 will be announced later than in prior years, and a results date and an
update on the review of strategic options will be announced in due course.

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Daniel Lee, Chief Executive Officer          via Walbrook PR

 David Cocke, Chief Financial Officer

 Cavendish Capital Markets (Nominated Adviser and Broker)                         Tel: +44 (0) 20 7466 5000
 Geoff Nash/Giles Balleny/Edward Whiley
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)            Tel: +44 (0)20 7933 8780
 Alice Woodings / Lianne Applegarth           Tissue Regenix@walbrookpr.com (mailto:TissueRegenix@walbrookpr.com)

 

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech
company specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing opportunities in
defects created by trauma and disease. CellRight's human tissue products may
be used in spine, trauma, general orthopaedic, dental and ophthalmological
surgical procedures.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFLEVVIDLIE